Progress in TB preventive therapy

doi:10.3969/j.issn.1000-6621.2014.01.013

Abstract

LIU Er-yong, CHENG Shi-ming, LAI Yu-ji, WANG Dong-mei, LI Tao, WANG Li-ming, WANG Ni, XU Xiao-yu, ZHOU Lin. Progress in TB preventive therapy[J]. Chinese Journal of Antituberculosis, 2014, 36(1): 59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013

References

［1］Corbett EL，Watt CJ,Maher D, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med, 2003,163(9): 1009-1021.
［2］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 2000,161(4 Pt 2): S221-247.
［3］刘二勇，周林，成诗明.结核分枝杆菌潜伏性感染及预防性治疗研究进展的系统评价.中国防痨杂志，２０１３,３５（４）：231-238.
［4］Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc, 1970,26: 28-106.
［5］Ferebee SH, Mount FW. Chemotherapy of tuberculosis, progress and promise. Public Health Rep, 1957, 72(5): 412-420.
［6］Ferebee SH, Mount FW, Palmer CE. Tuberculosis prophylaxis trials in preview. Public Health Rep, 1957, 72(8): 703-704.
［7］Ferebee S, Mount FW, Anastasiades A. Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report. Am Rev Tuberc, 1957, 76(6): 942-963.
［8］Comstock GW, Ferebee SH, Hammes LM, A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis, 1967, 95(6): 935-943.
［9］Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis, 1962, 85: 490-510.
［10］Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology, 2010, 15(4): 603-622.
［11］Mount FW， Ferebee SH.The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis, 1962, 85: 821-827.
［12］Ferebee SH,Mount FW,Murray FJ, et al. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis, 1963, 88:161-175.
［13］Grzybowski S, Ashley MJ,mckinnon NE,et al. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Can Med Assoc J, 1969, 101(9): 81-86.
［14］Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J, 1976, 114(7): 607-611.
［15］Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA, 1986, 255(12):1579-1583.
［16］［No authors listed］.Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982, 60(4): 555-564.
［17］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000, 49(RR-6): 1-51.
［18］Long R. The Canadian Lung Associsation/Canadian Thoracic Society and tuberculosis prevention and control. Can Respir J, 2007, 14(7):427-431.
［19］Menzies D, Jahdali H Al,Otaibi B Al. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res, 2011, 133(3):257-266.
［20］Comstock GW,Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis, 1979, 119(5):827-830.
［21］Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis, 1999, 3(10): 847-850.
［22］Selwyn PA,Hartel D,Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med, 1989, 320(9): 545-550.
［23］Akolo C,Adetifl I,Shepperd S,et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010,20(1): CD000171.
［24］Cain KP,McCarthy KD,Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med, 2010, 362(8):707-716.
［25］World Health Organization.Policy statement on preventive therapy against tuberculosis in people living with HIV. Geneva: World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS, 1998.
［26］World Health Organization.Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings. Geneva:World Health Organization,2011.
［27］Martinson NA,Barnes GL,Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med, 2011, 365(1): 11-20.
［28］Balcells ME, Thomas SL,godfrey-faussett P,et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis, 2006, 12(5): 744-751.
［29］Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis, 1978, 117(6):991-1001.
［30］Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associa-ted with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA, 1999, 281(11): 1014-1018.
［31］LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med, 2003, 168(4): 443-447.
［32］Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis, 1989, 140(5):1189-1193.
［33］Gao XF,Wang L,Lin GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis, 2006, 10(10):1080-1090.
［34］Gordin F,Chaisson RE,Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA, 2000, 283(11):1445-1450.
［35］Halsey NA,Coberly JS,Desormeaux J, et al., Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, 1998, 351(9105):786-792.
［36］Ijaz K,Jereb JA,Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis, 2006, 42(3):346-355.
［37］Centers for Disease Control and Prevention,American Thoracic society.Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep, 2003, 52(31):735-739.
［38］Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis, 2010, 14(11): 1374-1381.
［39］Schechter M, Zaidenverq T,falco G,et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med, 2006, 173(8):922-926.
［40］Sterling TR, Villarino ME,Borisov AS,et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166.
［41］Centers for Disease Control and Prevention.Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep, 2011, 60(48):1650-1653.
［42］Dorman SE，Johnson JL,Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med, 2009, 180(3): 273-280.

[1]	ZHAO Ben-nan, LIU Da-feng, LIU Ya-ling, YANG Ming, LAN Li-juan, DU Qing. Clinical analysis of hypothyroidism after anti-tuberculosis treatment in patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 465-471.
[2]	consensus on diagnosis and treatment of drug-resistant spinal tuberculosis writing group Expert. Expert consensus on diagnosis and treatment of drug-resistant spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2019, 41(4): 377-382.
[3]	FAN Lin,XIONG Kun-long,XIAO He-ping. Historic review of anti-tuberculosis chemotherapy during seventy years of the People’s Republic of China [J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1145-1148.
[4]	Wen-wen SUN,Hai LOU,Qin SUN. Short-time efficacy of regimen containing rifabutin in patients with slowly growing mycobacterium lung disease [J]. Chinese Journal of Antituberculosis, 2018, 40(9): 948-953.
[5]	Long JIN,Wei-hua HU,Shui-hua LU. Effect of diabetes mellitus on multidrug-resistant pulmonary tuberculosis and the countermeasures [J]. Chinese Journal of Antituberculosis, 2018, 40(9): 999-1002.
[6]	Clinic Society of Chinese Antituberculosis Association. Annual report on clinical diagnosis and treatment progress of tuberculosis (2013) (Part 2 clinical treatment) [J]. Chinese Journal of Antituberculosis, 2014, 36(9): 830-854.
[7]	XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian. The past, present and future of study in the chemotherapy of drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2014, 36(8): 634-637.
[8]	TANG Shen-jie, LIU Yi-dian, ZHANG Zhan-jun, XIAO He-ping, WAN Li-ya. Issues in selection of treatment regimen for multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2014, 36(7): 521-524.
[9]	DING Xiao-yan, XU Wei-guo, ZHU Li-mei, ZHOU Yang, SHAO Yan, SONG Hong-huan, PAN Hong-qiu, LING Su-ping, SUN Jian-sheng, WU Yun-liang, GU Xin-rong, LU Feng, LU Wei. Analysis on the treatment outcome of 175 multidrug-resistant pulmonary tuberculosis cases [J]. Chinese Journal of Antituberculosis, 2014, 36(4): 238-243.
[10]	ZHANG Yan，ZHANG Jin-guo，FANG Deng-lou，ZHANG Yong-qiang，ZHANG Bao-zong. Analysis of clinical effect of alternate day therapy with fixed-dose combinations of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2014, 36(1): 41-45.
[11]	HONG Feng, GAO Zhi-dong, LI Bo, SUN Shan-hua, ZHAO Xin. Evaluation of multidrug-resistant tuberculosis control in 5 years in Beijing [J]. Chinese Journal of Antituberculosis, 2013, 35(9): 706-710.
[12]	ZHAO Yong，LIU Xin. Observation of therapeutic effect of rifabutin on retreatment smear-positive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2013, 35(7): 525-528.
[13]	LI Li-tao, MA Yuan-zheng,LI Da-wei,CUI Xu, HU Ming, LUO Xiao-bo. Retrospective study of surgery combined with individualized chemotherapy for patients with multi-drug resistant spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2013, 35(5): 317-321.
[14]	LUO Ping, TU De-hua, HONG Feng, WANG Jing, WANG Su-min, ZHANG Tian-hao. Effect analysis on standard regimens of retreatment pulmonary tuberculosis in 177 cases [J]. Chinese Journal of Antituberculosis, 2013, 35(5): 347-351.
[15]	LIU Er-yong, ZHOU Lin, CHENG Shi-ming. Systematic review of latent tuberculosis infection and tuberculosis preventive therapy [J]. Chinese Journal of Antituberculosis, 2013, 35(4): 231-239.